What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.

Testa, L; Bhindi, R; Van Gaal, W J; Latini, R A; Pizzocri, S; Lanotte, S; Biondi Zoccai, G G L; Valgimigli, M; Laudisa, M L; Brambilla, N; Banning, A P; Bedogni, F

Testa, L; Bhindi, R; Van Gaal, W J; Latini, R A; Pizzocri, S; Lanotte, S; Biondi Zoccai, G G L; Valgimigli, M; Laudisa, M L; Brambilla, N; Banning, A P; Bedogni, F.

Affiliation

Testa L; Department of Interventional Cardiology, S Ambrogio Clinical Institute, Milan, Italy. luctes@gmail.com

QJM ; 103(6): 367-77, 2010 Jun.

Article in En | MEDLINE | ID: mdl-20211848

Subject(s)

Piperazines/therapeutic use; Platelet Aggregation Inhibitors/therapeutic use; Receptors, Purinergic P2/therapeutic use; Thiophenes/therapeutic use; Ticlopidine/analogs & derivatives; Clopidogrel; Drug Evaluation, Preclinical; Hemorrhage/complications; Humans; Piperazines/antagonists & inhibitors; Piperazines/pharmacokinetics; Platelet Aggregation Inhibitors/pharmacokinetics; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes/antagonists & inhibitors; Thiophenes/pharmacokinetics; Ticlopidine/pharmacokinetics; Ticlopidine/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Thiophenes / Ticlopidine / Platelet Aggregation Inhibitors / Receptors, Purinergic P2 Type of study: Clinical_trials / Etiology_studies / Systematic_reviews Limits: Humans Language: En Journal: QJM Year: 2010 Document type: Article

Fulltext

XML

PubMed Links

Search on Google